HRP20211197T1 - Rekombinantni glikoproteini i njihova uporaba - Google Patents
Rekombinantni glikoproteini i njihova uporaba Download PDFInfo
- Publication number
- HRP20211197T1 HRP20211197T1 HRP20211197TT HRP20211197T HRP20211197T1 HR P20211197 T1 HRP20211197 T1 HR P20211197T1 HR P20211197T T HRP20211197T T HR P20211197TT HR P20211197 T HRP20211197 T HR P20211197T HR P20211197 T1 HRP20211197 T1 HR P20211197T1
- Authority
- HR
- Croatia
- Prior art keywords
- oligosaccharides
- percentage
- total
- peak
- rhaga
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 229920001542 oligosaccharide Polymers 0.000 claims 25
- 150000002482 oligosaccharides Chemical class 0.000 claims 24
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims 1
- -1 fucose oligosaccharides Chemical class 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70592—CD52
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Claims (14)
1. Rekombinantni humani protein α-galaktozidaze-A (rhAGA) koji ima:
postotak ukupnih N-vezanih oligosaharida u vrhu 11 koji su bis-manoza-6-fosforilirani oligosaharidi koji je veći od 9%;
postotak ukupnih N-vezanih oligosaharida u vrhu 3 koji su monosijalilirani, minus fukozni oligosaharidi koji je između 0.1% i 1.6%;
postotak ukupnih N-vezanih oligosaharida u vrhu 4 koji su bisijalilirani oligosaharidi koji sadrže fukozu koji je veći od 13.5 %;
postotak ukupnih N-vezanih oligosaharida u vrhu 6' koji su triantenarni, trisijalilirani oligosaharidi oblika 2 koji je veći od 2.0%;
postotak ukupnih N-vezanih oligosaharida u vrhu 1 koji su neutralno nabijeni oligosaharidi koji je između 0.1 % i 3 .9%;
postotak ukupnih N-vezanih oligosaharida u vrhu 2 koji su monosijalilirani oligosaharidi koji sadrže fukozu koji je između 0.1% i 3.0%;
postotak ukupnih N-vezanih oligosaharida u vrhu 5 koji su bisijalilirani oligosaharidi koji je između 0.1 % i 5.3%;
postotak ukupnih N-vezanih oligosaharida u vrhu 6 koji su triantenarni, trisijalilirani oligosaharidi oblika 1 koji je između 0.1% i 9.0%;
postotak ukupnih N-vezanih oligosaharida u vrhu 7 koji su manoza-6-fosforilirani oligosaharidi koji je između 1% i 7.0%;
postotak ukupnih N-vezanih oligosaharida u vrhu 8 koji su monofosforilirani oligosaharidi koji je veći od 14.8%;
postotak ukupnih N-vezanih oligosaharida u vrhu 9 koji su tetrasijalilirani oligosaharidi koji je veći od 4.9%; i
postotak ukupnih N-vezanih oligosaharida u vrhu 10 koji su monosijalilirani i monofosforilirani oligosaharidi koji je veći od 8.2%;
pri čemu se vrhovi određuju profiliranjem N-vezanih oligosaharida obilježenih antranilnom kiselinom.
2. Farmaceutski pripravak naznačen time što sadrži protein rhAGA prema patentnom zahtjevu 1, i farmaceutski prihvatljiv nosač.
3. Farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time što je pripravak formuliran za intravensku, intraarterijsku, intramuskularnu, intradermalnu, potkožnu ili intraperitonealnu primjenu
4. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time što farmaceutski pripravak sadrži koncentraciju rhAGA od 4 mg/mL do 6 mg/mL.
5. Farmaceutski pripravak prema patentnom zahtjevu 4, naznačen time što farmaceutski pripravak sadrži koncentraciju rhAGA od 5 mg/mL.
6. Farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time što je farmaceutski pripravak sterilni, liofilizirani prah.
7. Farmaceutski pripravak prema patentnom zahtjevu 6, naznačen time što je farmaceutski prihvatljiv nosač jedno ili više sredstava odabranih iz skupine koju čine: manitol, natrijev fosfat monobazni monohidrat i natrijev fosfat dvobazni heptahidrat.
8. Protein rhAGA prema patentnom zahtjevu 1 naznačen time što je za uporabu u liječenju Fabryjeve bolesti.
9. Protein rhAGA za uporabu prema patentnom zahtjevu 8, naznačen time što je navedena uporaba u postupku za povećanje razine proteina α-galaktozidaze-A u lizosomu u stanici sisavca kod subjekta, pri čemu je stanica sisavca u kontaktu s proteinom rhAGA.
10. Protein rhAGA za uporabu prema patentnom zahtjevu 8, naznačen time što je navedena upotreba u postupku za smanjenje razine globotriaozilceramida u serumu subjekta.
11. Protein rhAGA za uporabu prema bilo kojem od patentnih zahtjeva 8-10, naznačen time što se protein rhAGA primjenjuje intravenozno.
12. Protein rhAGA za uporabu prema patentnom zahtjevu 11, naznačen time što se protein rhAGA primjenjuje u dozi od 0.5 mg/kg tjelesne težine do 2.0 mg/kg tjelesne težine.
13. Protein rhAGA za uporabu prema patentnom zahtjevu 12, naznačen time što se protein rhAGA primjenjuje u dozi od 1.0 mg/kg tjelesne težine.
14. Protein rhAGA za uporabu prema bilo kojem od patentnih zahtjeva 8-10, naznačen time što se primjenjuju dvije ili više doza proteina rhAGA, pri čemu se najmanje dvije od dvije ili više doza proteina rhAGA primjenjuju u razmaku od dva tjedna.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| EP14796346.6A EP3060660B1 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211197T1 true HRP20211197T1 (hr) | 2021-11-12 |
Family
ID=51871299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211197TT HRP20211197T1 (hr) | 2013-10-23 | 2021-07-26 | Rekombinantni glikoproteini i njihova uporaba |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11208644B2 (hr) |
| EP (2) | EP3060660B1 (hr) |
| JP (2) | JP6837334B2 (hr) |
| KR (2) | KR102298080B1 (hr) |
| CN (3) | CN105916984A (hr) |
| AU (2) | AU2014340152A1 (hr) |
| BR (1) | BR112016008086A2 (hr) |
| CA (1) | CA2927852A1 (hr) |
| CL (1) | CL2016000961A1 (hr) |
| CR (1) | CR20160225A (hr) |
| DK (1) | DK3060660T3 (hr) |
| DO (1) | DOP2016000079A (hr) |
| EA (1) | EA034515B1 (hr) |
| ES (1) | ES2882562T3 (hr) |
| HR (1) | HRP20211197T1 (hr) |
| HU (1) | HUE055236T2 (hr) |
| IL (2) | IL245255B (hr) |
| LT (1) | LT3060660T (hr) |
| MX (1) | MX2016005321A (hr) |
| MY (2) | MY178632A (hr) |
| NZ (1) | NZ720384A (hr) |
| PE (1) | PE20160723A1 (hr) |
| PH (1) | PH12016500708A1 (hr) |
| PL (1) | PL3060660T3 (hr) |
| PT (1) | PT3060660T (hr) |
| RS (1) | RS62171B1 (hr) |
| SG (2) | SG10201803366PA (hr) |
| SI (1) | SI3060660T1 (hr) |
| TN (1) | TN2016000140A1 (hr) |
| TW (3) | TWI642782B (hr) |
| UA (1) | UA119857C2 (hr) |
| UY (1) | UY35794A (hr) |
| WO (1) | WO2015061464A2 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP7114485B2 (ja) * | 2016-05-18 | 2022-08-08 | モデルナティエックス インコーポレイテッド | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
| WO2018075736A1 (en) | 2016-10-20 | 2018-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| EP0935651B1 (en) | 1996-09-13 | 2004-12-29 | Transkaryotic Therapies, Inc. | THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| US7332303B2 (en) * | 2002-12-23 | 2008-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| CA3069431A1 (en) * | 2007-04-03 | 2008-10-09 | Oxyrane Uk Limited | Glycosylation of molecules |
| KR20100038235A (ko) | 2007-08-31 | 2010-04-13 | 에프. 호프만-라 로슈 아게 | 글리코실화 프로파일 분석 |
| WO2010122460A1 (en) * | 2009-04-20 | 2010-10-28 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| BR112012022029B1 (pt) * | 2010-03-02 | 2022-10-11 | Protalix Ltd | Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| PT3272861T (pt) * | 2011-01-20 | 2020-03-26 | Protalix Ltd | Construção de ácido nucleico para expressão de alfα-galactosidase em plantas e células de plantas |
| KR20140108519A (ko) * | 2011-10-12 | 2014-09-11 | 시나게바 바이오파르마, 코포레이션 | 재조합 인간 naglu 단백질 및 이의 용도 |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| SG10201709131UA (en) | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
-
2014
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active IP Right Grant
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active IP Right Grant
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en active Application Filing
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 MX MX2016005321A patent/MX2016005321A/es unknown
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en active Pending
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-15 PH PH12016500708A patent/PH12016500708A1/en unknown
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en active Pending
-
2021
- 2021-07-26 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211197T1 (hr) | Rekombinantni glikoproteini i njihova uporaba | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| JP2010248207A5 (hr) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2012515221A5 (hr) | ||
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| MX2013005341A (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2012180381A5 (hr) | ||
| HRP20240420T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| EP4218769A3 (en) | Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose | |
| BR112015011778A2 (pt) | métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2016505023A5 (hr) | ||
| JP2014513722A5 (hr) | ||
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| BR112015030881A2 (pt) | regime de dosagem e formulações para adenovírus de tipo b | |
| ZA202107431B (en) | Para-aminohippuric acid (pah) as a renal protective substance | |
| HRP20231652T1 (hr) | Peptidi za primjenu u liječenju oralnog mukozitisa | |
| JP2016503070A5 (hr) |